BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Newbridge Securities Forms BioVentures Division


2/17/2009 11:03:05 AM

Newbridge Expands its Presence in the Biotech Industry

FT. LAUDERDALE, Fla., Feb. 17 /PRNewswire/ -- Newbridge Securities Corporation ("Newbridge"), a full-service securities broker-dealer and investment bank, is proud to announce the formation of the Newbridge BioVentures Division ("NBV"). NBV is dedicated to providing investment banking services for the biotech industry and related investment opportunities for institutional and sophisticated individual investors.

We are pleased to announce Christopher Carra as the Managing Director of NBV. Mr. Carra has been a registered representative in the securities industry for over 16 years, primarily focused in the biotech sector. Mr. Carra has been involved in several private placements and initial public offerings for biotech companies, and is a founding member of NBV. Prior to joining Newbridge in 2005, Mr. Carra worked at several private-client focused firms, most recently Oppenheimer & Co., where he worked from 2000-2005 as a senior vice president.

Please visit the BioVentures website; it can be accessed through www.newbridgesecurities.com or www.investbiopharma.com.

"We are extremely excited to add NBV as a focus to our already diversified suite of businesses," said Guy S. Amico, Newbridge's president. "In addition, having powerful advisors, such as Dr. David Sherris, Ph.D., on the Scientific Advisory board will lend top-level credibility and research to enhance our success rate for our Institutional and Private Client Group clients."

About Newbridge

Newbridge Securities Corporation provides full service securities brokerage and investment banking services to a broad based group of individuals and corporate clients. Comprised of a committed and experienced team of financial service professionals, we seek to empower our clients to build and preserve wealth by providing superior financial services and products.

For more information on NBV, contact Christopher Cara at 561.391.1220 (email at ccara@newbridgesecurities.com) or visit our website at www.newbridgesecurities.com.

CONTACT: Christopher Cara of Newbridge Securities Corporation,
+1-561-391-1220, ccara@newbridgesecurities.com

Web site: http://www.investbiopharma.com/
http://www.newbridgesecurities.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES